BCI
JANX icon

Brinker Capital Investments’s Janux Therapeutics JANX Stock Holding History

Brinker Capital Investments’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,913
Closed -$263K – 1933
2024
Q4 		$263K Sell
4,913
-1,692
-26% -$89.5K ﹤0.01% 1616
2024
Q3 		$300K Sell
6,605
-1,202
-15% -$52.3K ﹤0.01% 1520
2024
Q2 		$327K Sell
7,807
-3,153
-29% -$148K ﹤0.01% 1433
2024
Q1 		$413K Buy
+10,960
New +$239K ﹤0.01% 1350

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Brinker Capital Investments's JANX Position: Q1 2025 in Review

Brinker Capital Investments sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 4,913 shares — an estimated $263K sold.

Brinker Capital Investments first reported a position in JANX in Q1 2024 and held it in 4 quarters. The position peaked at $413K in Q1 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Brinker Capital Investments reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Brinker Capital Investments sold 4,913 Janux Therapeutics shares in Q1 2025, an estimated $263K.
  • Brinker Capital Investments first reported a position in Janux Therapeutics in Q1 2024 and held it in 4 quarters.
  • Brinker Capital Investments's Janux Therapeutics position peaked at $413K in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Brinker Capital Investments's 13F filing for Q1 2025, filed 1 Aug 2025.